Epicrispr Reports First Clinical Evidence of Increased Lean Muscle Volume in Patients with FSHD Following Treatment with EPI-321

Single-Dose EPI-321 Demonstrated a Positive Safety Profile and Increased Lean Muscle Volume Across the First Three Evaluable Patients at Six MonthsEPI-321 is the First Investigational Therapy Designed to Silence DUX4, the Genetic Driver of FSHD SAN FRANCISCO, CA – June 26, 2026 – Epicrispr Biotechnologies, a clinical-stage company pioneering epigenetic therapies, today announced new interim … Read more